Disposition of 11245 shares by Blackman Samuel C. of Day One at 16.0326 subject to Rule 16b-3
TSHA Stock | USD 3.24 0.24 8.00% |
About 63% of all Taysha Gene's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Taysha Gene Therapies suggests that some traders are interested. The current market sentiment, together with Taysha Gene's historical and current headlines, can help investors time the market. In addition, many technical investors use Taysha Gene Therapies stock news signals to limit their universe of possible portfolio assets.
Taysha |
Filed transaction by Day One Biopharmaceuticals Officer: Head Of R&d. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at gurufocus.com
Taysha Gene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Taysha Gene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Taysha Gene Fundamental Analysis
We analyze Taysha Gene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Taysha Gene is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Taysha Gene Therapies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Taysha Gene stock to make a market-neutral strategy. Peer analysis of Taysha Gene could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics with similar companies.
Peers
Taysha Gene Related Equities
CABA | Cabaletta Bio | 26.91 | ||||
GLUE | Monte Rosa | 13.72 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
PRLD | Prelude Therapeutics | 7.14 | ||||
BMEA | Biomea Fusion | 3.13 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
HOOK | Hookipa Pharma | 1.61 | ||||
ALEC | Alector | 1.57 | ||||
DAWN | Day One | 1.53 | ||||
STTK | Shattuck Labs | 0.92 | ||||
AKRO | Akero Therapeutics | 0.22 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
GOSS | Gossamer Bio | 1.41 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
LRMR | Larimar Therapeutics | 4.67 | ||||
ELYM | Eliem Therapeutics | 5.88 |
Complementary Tools for Taysha Stock analysis
When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |